Related Experiment Videos
Vanadium in cancer treatment
1Faculty of Medicine, Laboratory of Physiology, University of Ioannina, Ioannina, Greece. aevaggel@cc.uoi.gr
Abstract:
Vanadium compounds exert preventive effects against chemical carcinogenesis on animals, by modifying, mainly, various xenobiotic enzymes, inhibiting, thus, carcinogen-derived active metabolites. Studies on various cell lines reveal that vanadium exerts its antitumor effects through inhibition of cellular tyrosine phosphatases and/or activation of tyrosine phosphorylases. Both effects activate signal transduction pathways leading either to apoptosis and/or to activation of tumor suppressor genes. Furthermore, vanadium compounds may induce cell-cycle arrest and/or cytotoxic effects through DNA cleavage and fragmentation and plasma membrane lipoperoxidation. Reactive oxygen species generated by Fenton-like reactions and/or during the intracellular reduction of V(V) to V(IV) by, mainly, NADPH, participate to the majority of the vanadium-induced intracellular events. Vanadium may also exert inhibitory effects on cancer cell metastatic potential through modulation of cellular adhesive molecules, and reverse antineoplastic drug resistance. It also possesses low toxicity that, in combination with the synthesis of new, more potent and better tolerated complexes, may establish vanadium as an effective non-platinum, metal antitumor agent.
Insights
Vanadium compounds show promise as antitumor agents by inhibiting cancer cell growth and metastasis. Their low toxicity and ability to overcome drug resistance make them potential non-platinum metal alternatives.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Vanadium compounds demonstrate preventive effects against chemical carcinogenesis in animal models.
- Cell line studies indicate vanadium's antitumor mechanisms involve modulating xenobiotic enzymes and tyrosine kinases.
Purpose of the Study:
- To explore the multifaceted antitumor mechanisms of vanadium compounds.
- To evaluate vanadium's potential as a non-platinum metal-based chemotherapeutic agent.
Main Methods:
- Investigating the impact of vanadium on xenobiotic enzymes and cellular tyrosine phosphatases/phosphorylases.
- Analyzing vanadium-induced effects on apoptosis, tumor suppressor gene activation, cell-cycle arrest, and DNA damage.
- Examining the role of reactive oxygen species (ROS) in vanadium's intracellular actions.
- Assessing vanadium's effects on cancer cell metastasis and drug resistance.
Main Results:
- Vanadium modifies xenobiotic enzymes, inhibiting carcinogen activation and antitumor effects via tyrosine kinase modulation.
- Vanadium induces apoptosis, activates tumor suppressor genes, causes cell-cycle arrest, DNA cleavage, and lipoperoxidation.
- Reactive oxygen species (ROS) play a significant role in vanadium's intracellular effects.
- Vanadium inhibits metastasis and reverses drug resistance, exhibiting low toxicity.
Conclusions:
- Vanadium compounds possess diverse antitumor properties, including antiproliferative, pro-apoptotic, and anti-metastatic effects.
- Modulation of signaling pathways and induction of cellular damage contribute to vanadium's anticancer activity.
- Vanadium's low toxicity and potential to overcome drug resistance position it as a promising non-platinum metal antitumor agent.